Thrombolysis in Pediatric Stroke Study

Исследование тромболитической терапии при инсульте у детей
Gabrielle deVeber, Adam Kirton, Anthony K.C. Chan, Michael D. Hill, Anikó Szabó, Rebecca Ichord, Michael J. Rivkin, Catherine Amlie‐Lefond, Joan Cox Gill, Collin A. Hovinga, Kelley Scholz
2015-01-23

intracranial hemorrhagepediatric stroketPA pharmacokineticsthrombolysistissue plasminogen activator
S troke is an important acute neurological condition in chil- dren with an annual incidence ranging from 2.3 to 13 per 100 000 children. [1][2][3] Although most children who experience stroke do not die of the acute disorder, the consequences of the brain injury are amortized during the lengthy life span that follows.[4][5][6][7][8] The reduction potential in lifelong morbidity by timely and effective intervention with a thrombolytic agent, such as tissue-type plasminogen activator (tPA), in children with acute arterial ischemic stroke (AIS) constituted the core rationale for the study of tPA treatment of acute AIS in children.The perceived high potential for benefit after treatment justified assumption of risk for intracranial hemorrhage (ICH) after its use.9 Because in adults, the risk of hemorrhage after tPA use was thought to be related to infarct volume; this principle was assumed for children.The known developmental trajectory of the fibrinolytic system includes lower levels of endogenous tPA and higher levels of plasminogen activator inhibitor-1 in young children than are found in adults and warranted a dose-finding study beginning at doses lower than that used in adults with incremental increase through the currently used adult dose of 0.9 mg/kg and careful assessment of tPA pharmacokinetics.10 Currently, information on children treated with tPA consists of case reports, small case series, and hospital database documentation.Best practice for the treatment of children with acute stroke has received little rigorous study.Clinical approach varies widely among centers and reflects a dearth of research on which to base treatment protocols.Although tPA is not approved for use in childhood stroke, ≤2% of children with acute stroke are reported to have been treated with tPA in the United States, despite lack of safety and efficacy data.[11][12][13][14] In 2010, the National Institute of Neurological Disorders and Stroke (NINDS) funded the first prospective treatment trial in acute pediatric stroke, the Thrombolysis in Pediatric Stroke (TIPS) trial (National Institutes of Health [NIH] grant R01NS065848).TIPS reflected a multi-institutional, multidisciplinary design to determine safety, best dose, and feasibility of treatment with intravenous (IV) tPA of children who present with AIS.Secondary aims comprise the determination of the pharmacokinetics of tPA in children and assessment of the 90-day clinical outcome among treated patients.TIPS was closed by the NIH in December 2013 for lack of accrual.Herein, we summarize the lessons learned during the development and initial execution of the TIPS trial, the protocol synopsis, and the results of the challenges in implementation of the study.The occurrence of symptomatic ICH after the use of tPA in children with acute ischemic stroke constitutes a principal concern.When administered to adults according to NINDS guidelines, IV tPA therapy for AIS is associated with symptomatic ICH in 6.4%.15 This risk may be lower in younger patients because none of the 48 young adults (16-49 years of age) treated with IV tPA for AIS developed symptomatic ICH.16 In adults with acute stroke, increasing hemorrhagic volume after IV tPA treatment correlated with increasingly poor neurological outcome.17 During childhood, the fibrinolytic system is not yet mature.10,[18][19][20] Baseline-free tPA concentration is decreased and plasminogen activator inhibitor-1 concentration, an inhibitor of tPA, is increased in children compared with that in adults.20,21 In addition, children have an increased volume of distribution 22,23 and more rapid hepatic clearance, suggesting that they will clear tPA more quickly.24 This raises the possibility that a
1
Because hemorrhage risk was assumed to correlate with infarct volume in adults, the same principle was applied to children.
2
Before this study, pediatric tPA evidence consisted mainly of case reports, small case series, and hospital databases, with substantial variation in clinical practice.
3
Developmental differences in fibrinolysis, including lower endogenous tPA and higher plasminogen activator inhibitor-1 levels in young children, motivated pediatric dose-finding.
4
The protocol began below the adult alteplase dose and incrementally increased to 0.9 mg/kg while carefully assessing tPA pharmacokinetics.
5
The study was justified by potential treatment benefits despite the risk of intracranial hemorrhage after thrombolysis in pediatric stroke.

Children with acute ischemic stroke treated with tissue plasminogen activator (tPA)

Safety, dose selection, pharmacokinetics, and clinical treatment practices for tPA thrombolysis, particularly the risk of intracranial hemorrhage (ICH)

Publication Details
Publication Date
2015-01-23
Journal
Publisher
ISSN
Cited by
249
Access Type
Author Information
Authors
Gabrielle deVeber
Adam Kirton
Anthony K.C. Chan
Michael D. Hill
Anikó Szabó
Rebecca Ichord
Michael J. Rivkin
Catherine Amlie‐Lefond
Joan Cox Gill
Collin A. Hovinga
Kelley Scholz
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%